eXTReMe Tracker
Gene Therapy Net RSS feed Follow Gene Therapy Net on Twitter LinkedIn - Gene Therapy Net discussion group Facebook - Gene Therapy Net

International Consortium

Related Links

uniQure's Glybera® First Gene Therapy Approved by European Commission

Posted on: 2 November 2012, source: uniQure
uniQure announced today it has received approval from the European Commission for the gene therapy Glybera® (alipogene tiparvovec), a treatment for patients with lipoprotein lipase deficiency (LPLD, also called familial hyperchylomicronemia) suffering from recurring acute pancreatitis. Patients with LPLD, a very rare, inherited disease, are unable to metabolize the fat particles carried in their blood, which leads to inflammation of the pancreas (pancreatitis), an extremely serious, painful, and potentially lethal condition. The approval makes Glybera the first gene therapy approved by regulatory authorities in the Western world.

Register to read more ...

DNA folded into shapes offers alternative gene delivery vehicle

Posted on: 18 October 2012, source: Nanowerk News
Researchers from Johns Hopkins and Northwestern universities have discovered how to control the shape of nanoparticles that move DNA through the body and have shown that the shapes of these carriers may make a big difference in how well they work in treating cancer and other diseases. This study, published in the Oct. 12 online edition of Advanced Materials is also noteworthy because this gene therapy technique does not use a virus to carry DNA into cells. Some gene therapy efforts that rely on viruses have posed health risks.

Register to read more ...

EMA Streamlines Working Parties

Posted on: 25 September 2012, source: PharmTech
The European Medicines Agency (EMA) has abolished its Cell-based Product Working Party (CPWP) and Gene Therapy Working Party (GTWP), with the aim of improving efficiencies and optimizing the use of available expertise. Instead, EMA’s Committee for Advanced Therapies (CAT) will be assuming the lead role in all aspects concerning the development of advanced-therapy medicines in Europe, including developing guidelines, organizing workshops and establishing ad-hoc draft groups as and when required to develop specific guidance documents. Guidance documents already being developed by CPWP or GTWP will be taken over by the new drafting groups

Register to read more ...

Researchers Improve Gene Therapy Technique for Children with Immune Disorder

Posted on: 12 September 2012, source: Healthcare Globa
Researchers enhance gene therapy approach for children with adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID) using chemotherapy as conditioning regimen. For the first time, investigators test two different viral vectors to transport normal genes into the young patients' bone marrow stem cells and two different treatment plans in preparation for receiving gene therapy and compare outcomes.

Register to read more ...

Scientists restore sense of smell in mice through gene therapy

Posted on: 3 September 2012, source: News-Medical
Scientists have restored the sense of smell in mice through gene therapy for the first time -- a hopeful sign for people who can't smell anything from birth or lose it due to disease. The achievement in curing congenital anosmia -- the medical term for lifelong inability to detect odors -- may also aid research on other conditions that also stem from problems with the cilia. Those tiny hair-shaped structures on the surfaces of cells throughout the body are involved in many diseases, from the kidneys to the eyes. The new findings, published online in Nature Medicine, come from a team at the University of Michigan Medical School and their colleagues at several other institutions

Register to read more ...

The cheat gene: Could the next step in sporting fraud come from manipulating DNA?

Posted on: 22 August 2012, source: The Independent
The London Olympics may turn out to be one of the cleanest in history in terms of banned substances – but behind the scenes, scientists fear the next big challenge to fair play in sport: gene doping. Over the past decade, scientific advances in the understanding of how genes control muscle activity have alarmed experts within the World Anti-Doping Agency (Wada) who believe that using genes, rather than drugs, will be the next way illicitly to boost athletic performance without fear of detection.

Register to read more ...

European Agency Recommends Gene Therapy Approval

Posted on: 22 July 2012, source: TodayOnline
European regulators have recommended approval of the Western world's first gene therapy drug - after rejecting it on three previous occasions - in a significant advance for the novel medical technology. More than 20 years since the first experiments with the ground-breaking method for fixing faulty genes, scientists and drug companies are still struggling to apply gene therapy in practice. Friday's decision by the European Medicines Agency (EMA) is a win for the drug's maker, the small Dutch biotech company uniQure, and a potential lifeline for patients with the ultra rare genetic disorder lipoprotein lipase deficiency (LPLD).

Register to read more ...

Nanoparticles Deliver Gene Therapy Directly to Skin Cells

Posted on: 5 July 2012, source: GEN
Scientists have developed an siRNA-carrying gold nanoparticle that they claim can be mixed with a commercial moisturizing cream to enable the topical delivery of gene-targeting therapeutics directly into deep skin layers. The Northwestern University team says the platform could lead to the development of topical forms of gene therapy for diseases such as skin cancer, inflammation, and genetic skin disorders.

Register to read more ...

Bluebird wins orphan drug designation for ALD treatment

Posted on: 20 June 2012, source: Boston Herald
Cambridge-based genetic disorder drug maker bluebird bio said today it has received an orphan drug designation from both the U.S. Food and Drug Administration and the European Medicines Agency for its investigational gene therapy designed to treat adrenoleukodystrophy. Known as ALD, adrenoleukodystrophy is a rare, inherited disorder that leads to progressive brain damage, failure of the adrenal glands and ultimately death. The company said it plans to initiate a Phase 2/3 clinical study in childhood cerebral ALD in both the U.S. and Europe next year.

Register to read more ...

Gene Therapy Society Looking to NIH to Revisit Role of the Recombinant DNA Advisory Committee

Posted on: 7 June 2012, source: GEN
The principal U.S. professional society representing gene therapists is awaiting word from NIH about whether or not there will be re-examination of the role of its Recombinant DNA Advisory Committee (RAC). They aim to limit its longstanding role in clinical trials while continuing its service as a forum for discussing and educating professionals on policy issues. The American Society of Gene & Cell Therapy (ASGCT) touched off the debate earlier this year, when its president and her predecessor conveyed the society’s view that RAC should focus on broader issues rather than review the clinical protocols of individual researchers. They sent a letter to Amy Patterson, M.D., director of NIH’s Office of Biotechnology Activities (OBA), and issued a statement seven days later at a RAC meeting.

Register to read more ...

Targeting DNA: After 20 years of high-profile failure, gene therapy is finally well on its way to clinical approval

Posted on: 6 June 2012, source: The Scientist
The concept is simple: if a mutated gene is causing a problem, replace or supplement it with a new, accurate copy. In theory, such a strategy could not just treat, but cure countless human genetic diseases. In practice, however, developing safe and effective gene therapies has not been easy. Even when identifying a disorder’s genetic basis is fairly straightforward, finding the appropriate delivery vector to target the diseased tissues in the body, while avoiding unintended consequences, has challenged would-be gene therapists for more than 20 years. But more and more researchers are convinced that the technique is on the brink of becoming a common medical practice.

Register to read more ...

RetroSense Therapeutics Completes pre-IND Meeting for RST-001

Posted on: 31 May 2012, source: PipelineReview
RetroSense Therapeutics, a gene therapy company dedicated to vision restoration, announced completion of a pre-IND meeting with the Center for Biological Evaluation and Research (CBER) division of the FDA that took place on May 22nd 2012 regarding RetroSense’s lead biologic, RST-001 for vision restoration in retinal degenerative conditions. The purpose of the meeting was to obtain CBER’s guidance for the clinical path to a Biologics License Application (BLA) for RST-001 in the US, and clarity on the steps required for Investigational New Drug (IND) submission. The discussions included manufacturing criteria, the scope and design of the preclinical studies, and the scope and design of Phase I and IIa clinical trials.

Register to read more ...

Gene Therapy in Ophthalmology Clinical Trial Details: An Attempt to Track the Number of Patients Treated to Date

Posted on: 20 May 2012, source: Irv Arons
In attempting to determine how many patients had been treated with gene therapy for eye disorders, Irv Arons quickly found that no one was keeping track – at least no one that he could find. So, Irv Arons decided to try and get this data. He has now found reliable data for more than two-thirds of the 15 clinical trials underway and presents this information in his new table.

Register to read more ...

Gene Therapy Safe in Decade-Long HIV Study That May Widen Use

Posted on: 3 May 2012, source: BloombergNews
HIV patients given gene therapy more than a decade ago are healthy and the altered DNA they received remains stable in their bodies, according to a study that scientists say proves the treatment may safely be tested as a way to attack other illnesses. All except two of 43 people treated with genetically- altered versions of their own infection-fighting T cells were healthy as many as 11 years later, according to the research reported today in the journal Science Translational Medicine.

Register to read more ...

Top Cancer Scientists Converge to Celebrate ACGT's 10th Anniversary and New Frontiers in Treating Cancer

Posted on: 19 April 2012, source: ACGT
More than 30 of the nation's top cancer research scientists are gathering in Greenwich, Conn., this week to compare notes, collaborate, and celebrate ACGT's 10 years of innovative cancer research funding. ACGT was the funding arm of the breakthrough Leukemia clinical trial study at the University of Pennsylvania last summer that obliterated the cancer in patients.

Register to read more ...

Brain gene therapy is beating my Parkinson's

Posted on: 14 April 2012, source: WRAL
Doctors in Britain say a radical new treatment for Parkinson's could improve the lives of millions who suffer from the disease. Sheila Roy says she can finally enjoy life at her countryside home in Cambridge, England. She has lived with Parkinson's disease for 17 years, but a team of Oxford scientists developed a treatment that changed her life. “I can see a glimmer of a person I use to be now, which is really exciting,” she said. Roy was one of only 15 people in the world to take part in a gene therapy experiment that was previously tested on lab animals. Scientists create and inject a virus into the brain. It jumpstarts the production of dopamine, a chemical that fights Parkinson's. Without dopamine, patients suffer tremors and uncontrolled movements.

Register to read more ...

Potential gene therapy for patients with rare disease

Posted on: 13 April 2012, source: MedicalXpress
Australian scientists have discovered that a biological phenomenon known as ‘somatic reversion’, when an abnormal gene spontaneously becomes normal again, explains why some patients with a rare genetic disorder live much longer than they should.

Register to read more ...

Study shows developing a gene therapy for cancer will be harder than scientists thought

Posted on: 15 March 2012, source: Tampa Bay Times
Scientists working to customize cancer treatment based on each person's genes are finding new evidence of just how tough this task will be. In a single tumor, there are big differences as to which genes are active or mutated. Nor are the genetics of a single tumor and where it has spread consistent. This means that the single biopsies that doctors rely on to choose drugs are probably not giving a true view of the cancer's biology.

Register to read more ...

CHMP asks AMT to provide additional information on Glybera

Posted on: 22 February 2012, source: Pharmabiz.com
Amsterdam Molecular Therapeutics (AMT), a leader in the field of human gene therapy, has received a request to provide additional information to the Committee for Human Medicinal Products (CHMP) on Glybera (alipogene tiparvovec) by March 8, 2012. The CHMP request follows the announcement on January 30, 2012 that the European Commission Standing Committee was requesting additional information from the CHMP. The CHMP has indicated that a final decision on Glybera could be made by May 2012.

Register to read more ...

ACGT 2012 Investigator's Award in Clinical Translation of Gene Therapy for Pancreatic Cancer,

Posted on: 16 February 2012, source: ACGT Foundation
The Alliance for Cancer Gene Therapy, Inc. (ACGT) funds research aimed at furthering the development of gene therapy approaches to the treatment of cancer. To this end, ACGT offers awards in Clinical Translation of Gene Therapy for Cancer, to qualified scientists at the assistant professor level and above. This award is specifically for those conducting Gene Therapy Research for Pancreatic Cancer and is entitled, 2012 Investigator’s Award in Clinical Translation of Gene Therapy for Pancreatic Cancer. Abstract Deadline: March 7, 2012

Register to read more ...

NVGCT launches new website

Posted on: 3 February 2012, source: NVGCT
Since gene and cell therapy are closely related and actually intertwined scientific disciplines aiming at expanding and innovating the therapeutic arsenal for many so far incurable diseases, the Netherlands Society of Gene and Cell Therapy (NVGCT) now includes cell therapy in its name. Its new web site (www.nvgct.nl), launched February 1, 2012, aims at fostering further development and communicating progress.

Register to read more ...

Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation And Requests Further Information From the CHMP

Posted on: 30 January 2012, source: PRNewswire
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, was informed on Friday January 27, 2012 after business hours that the European Commission's Standing Committee of the European Parliament discussed on Monday January 22, 2012 the implementation decision not to grant marketing authorization for Glybera (alipogene tiparvovec) as recommended by the Committee for Human Medicinal Products (CHMP). After the discussion no clear position in favor or against granting a marketing authorization for Glybera was reached. Instead the Standing Committee considered it necessary to request additional information to the CHMP in the European Medicines Agency (EMA). A formal vote by the Standing Committee will be made on review of the additional information. It is currently unclear when a final decision will be reached.

Register to read more ...

HSCI Receives Approval To Market Neovasculgen – The First Russian Gene Therapy Drug For Treatment Of Peripheral Arterial Disease

Posted on: 21 December 2011, source: Human Stem Cell Institute (HSCI), Dr. Isaev
The Human Stem Cells Institute (“HSCI”, MICEX: ISKJ), Russia’s biotech company, announced today that it has received state approval for Neovasculgen® – the first Russian gene therapy drug to treat Peripheral Arterial Disease. The approval was received by HSCI on December 7, 2011, with the decision by the Russian Ministry of Healthcare and Social Development to include Neovasculgen® in the State Registry of Medications dating back to September 28, 2011. The decision was based on findings on the drug’s efficacy and safety reached during the pre-clinical and clinical trials carried out by HSCI. The Phase IIB/III clinical trials for Neovasculgen® were completed in Q2 2011, and in July HSCI submitted the relevant documentation to the Ministry for approval.

Register to read more ...

Gene therapy proves effective for hemophilia B

Posted on: 12 December 2011, source: Reuters
A single treatment with gene therapy, an experimental technique for fixing faulty genes, has been shown to boost output of a vital blood clotting factor, possibly offering a long-term solution for people with hemophilia B. Researchers said the same technology was also being studied as a treatment for hemophilia A, the far more common type of the inherited bleeding disorder.

Register to read more ...

Gene Therapy Video on the CliniGene Website

Posted on: 23 November 2011, source: CLinigene
On the CliniGene website you can find a 20 minutes video on Gene Therapy called: Gene Therapy a new tool to cure human diseases. This video is available directly at the following address: http://www.clinigene.eu/video-intro-gene-therapy.html. This video has been designed by Fatima Bosch, Carles Roca, Xavier Anguela and Albert Ruzo and is property of the Center for Animal Biotechnology and Gene Therapy of the Universitat Autónoma de Barcelona (UAB). The design of this video has been supported by CliniGene.

Register to read more ...

AMT Suspends Glybera and Plans 50% Job Cuts in Restructuring Moves

Posted on: 25 October 2011, source: AMT
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today provided an update on operations and disclosed the outcome of a strategic review of its gene therapy product pipeline conducted by management and AMT's Board of Directors that enables the company to remain at the forefront of gene therapy development. The CHMP's recent opinion, while not approving Glybera®, did not identify any safety risks with AMT's adeno-associated virus vector technology. This will allow AMT to leverage its expertise and strength in building other portfolio products. The selection of specific pipeline products is aimed at securing partnering agreements that will provide solid financial foundations to take the company forward. Existing shareholders continue to see promise in the technology and are in discussions with AMT to provide additional equity.

Register to read more ...

Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application

Posted on: 21 October 2011, source: PRNewswire
Amsterdam Molecular Therapeutics (AMT), a leader in the field of human gene therapy, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has maintained its earlier opinion that Glybera (alipogene tiparvovec) is not approvable at this time. The decision was made contrary to the positive recommendation of CHMP Rapporteurs, the Scientific Advisory Group (SAG), an expert panel specifically selected to evaluate clinical results and the science of the product, and the Committee for Advanced Therapies (CAT), which provides guidance on advanced therapeutics such as gene and cell therapy.

Register to read more ...

Gene therapy and stem cells unite

Posted on: 13 October 2011, source: BBC news
Two of the holy grails of medicine - stem cell technology and precision gene therapy - have been united for the first time in humans, say scientists. It means patients with a genetic disease could, one day, be treated with their own cells. A study in Nature corrected a mutation in stem cells made from a patient with a liver disease. Researchers said this was a "critical step" towards devising treatments, but safety tests were still needed.

Register to read more ...

Gene Therapists Celebrate a Decade of Progress

Posted on: 7 October 2011, source: Science
It has taken many years, but researchers may have reached a prized goal in gene therapy: lowering the risk of uncontrolled bleeding in patients with hemophilia. At a meeting last week, researchers reported that six patients who received a virus engineered to carry a gene for a blood-clotting protein called factor IX needed fewer transfusions of the protein for as long as 18 months; some didn't require any transfusions. One patient developed an immune response to the viral vector, but this side effect was successfully treated with drugs.

Register to read more ...

Sangamo gene therapy shows promise in reducing HIV

Posted on: 19 September 2011, source: Reuters
An early stage trial of Sangamo BioSciences Inc's HIV treatment found that the gene therapy reduced levels of the virus and even eliminated it in one patient with a naturally occurring gene mutation. The very small Phase 1 trial tested the SB-728-T gene therapy, which is designed to disrupt the CCR5 gene used by HIV to infect cells of the immune system. If shown to be safe and effective, the treatment could end the need for the antiretroviral drugs now used to keep the virus that causes AIDS in check by suppressing viral replication in the blood.

Register to read more ...